The Global Small Cell Lung Cancer Market: Prevalence, Treatment, and Market Players

The global market for small cell lung cancer is set to grow in the coming years, driven by the increasing prevalence of the disease. Small cell lung cancer is a sub-type of lung cancer that accounts for less than 20% of cases, and its treatment has proven challenging due to poor survival rates. The median overall survival for patients with small cell lung cancer is just over a year, and the overall progression-free survival is six months. Before the advent of immune checkpoint inhibitors, traditional chemotherapy was the mainstay of treatment, but these have now been incorporated into the standard treatment regimen.

The prevalence of small cell lung cancer is expected to increase in five of the seven major markets covered in the study. The US leads the way with an estimated prevalence of over 47,000 patients in 2021, followed by the UK with over 8,500 patients. The prevalence is forecast to grow at a CAGR of 2.61% and 1.61% respectively for the US and the UK for the period 2022-2032.

The global market for small cell lung cancer currently has two approved immune checkpoint inhibitors: Imfinzi (Durvalumab) from AstraZeneca and Tecentriq (Atezolizumab) from F. Hoffmann La-Roche. Zepzelca (Lurbinectedine) from Jazz Pharmaceuticals and Cosela (Trilaciclib) from G1 Therapeutics are also approved for the treatment of small cell lung cancer patients.

The introduction of immune checkpoint inhibitors to the treatment of small cell lung cancer has significantly increased competition in the global market. F. Hoffmann La-Roche and AstraZeneca are the leading players among companies with immune checkpoint inhibitor portfolios in the global small cell lung cancer market. Companies with immune checkpoint inhibitors in clinical development have also added small cell lung cancer treatment to their portfolios.

There are currently four patented products available in the market, while chemotherapeutic products that were once the standard of care have all become generic. The clinical pipeline for the small cell lung cancer market is rich, with a dominance of immune checkpoint inhibitors and bispecific antibodies.

The report provides an insight into the estimated patient population eligible for treatment in the seven major markets, with a view of where the disease is declining and where it is showing an increasing trend. Additionally, the report provides a comprehensive list of pipeline products, including clinical and commercial products, and their stage of development.

The report also examines the competitive landscape, providing profiles of key players in the small cell lung cancer market, including AstraZeneca, F. Hoffmann La-Roche, Jazz Pharmaceuticals, and G1 Therapeutics. The report identifies potential drivers of the market, such as the potential therapeutic effects of immune checkpoint inhibitors, and treatment aimed at reducing chemotherapy-induced toxic effects. The report also highlights challenges for the global small cell lung cancer market, such as treatment-related toxic effects and a lack of effective diagnostic tools and methods.

Overall, the report provides valuable insight into the small cell lung cancer market, including its size, growth potential, and key players. This information can be used by organizations to develop product and innovation strategies, as well as to identify potential partnerships and collaborations.

BHL1301SAPlease see more details: https://www.marketresearchdirect.com/report/the-global-small-cell-lung-cancer-market-prevalence-treatment-and-market-players/

Challenge House, Sherwood Drive, Milton Keynes, MK3 6DP ENGLAND UNITED KINGDOM

Market Research Direct is a single source for premium market research reports.

This release was published on openPR.